Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease
- Written by PR Newswire
 |
SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform. Having successfully advanced through single asending dose,SKY-0515 is advancing into the Multiple Ascending Dose portion of its phase 1 study. Huntington's disease is a fatal neurological disease with no curative therapies.
WALTH...
